Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients.

Creative Commons License

Cakirca M. , Karatoprak C. , Zorlu M. , Kiskac M. , Kanat M., CIKRIKCIOGLU M. A. , ...More

Drug design, development and therapy, vol.8, pp.239-43, 2014 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 8
  • Publication Date: 2014
  • Doi Number: 10.2147/dddt.s52545
  • Title of Journal : Drug design, development and therapy
  • Page Numbers: pp.239-43
  • Keywords: asymmetric dimethylarginine (ADMA), dipeptidyl peptidase-4 (DPP-4) inhibitor, vildagliptin, type 2 diabetes mellitus, GLUCAGON-LIKE PEPTIDE-1, MYOCARDIAL-INFARCTION, HEART-FAILURE, DYSFUNCTION, INHIBITION, RATS


Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.